Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tune Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is under the review of 1 distinct examiner, indicating a concentrated focus for the company. This arrangement facilitates a direct and consistent dialogue with the patent office regarding its biological innovations, allowing for a deep and thorough engagement with the examiner's feedback. Such a focused workload ensures that the company's technical arguments are clearly communicated and that its innovations are adequately protected in a highly competitive field.
The activity is located within a distinct art unit, which further suggests a specialized technical review process for the company's biotechnology. KONOPKA, CATHERINE ANNE, is the busiest examiner, currently managing the pending office action. The outcome of this prosecution will be a significant indicator of the company's patenting success in this field and will establish a baseline for its future intellectual property development. Practitioners should monitor the examiner's history and typical rejection patterns in this art unit to craft the most effective arguments for patentability and ensure a successful outcome.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293326 | COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF METHYL-CPG BINDING PROTEIN 2 (MECP2) | KONOPKA, CATHERINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293326 | COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF METHYL-CPG BINDING PROTEIN 2 (MECP2) | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293326 | COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF METHYL-CPG BINDING PROTEIN 2 (MECP2) | KONOPKA, CATHERINE ANNE | 1635 | §101§102§103§112DP | Non-Final OA | — | Pending | Jan 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTune Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Catherine Anne Konopka has the most, with 1 of Tune Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
